Literature DB >> 26722438

Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway.

Fen Ai1, Manhua Chen2, Bo Yu1, Yang Yang1, Guizhong Xu1, Feng Gui1, Zhenxing Liu1, Xiangyan Bai1, Zhen Chen1.   

Abstract

OBJECTIVE: The traditional Chinese medicinal berberine has long been used to treat cardiovascular diseases; however, the mechanism underlying its effects remains unclear. Here, this study would to investigate the effects of berberine on proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts.
METHODS: We assessed proliferation, collagen synthesis and cytokine secretion in cardiac fibroblasts subjected to angiotensin II (Ang II) subsequent to the consumption of berberine or a control treatment. And then we detected the role of AMPK/mTOR signaling pathway in berberine treatment of cardiac fibroblasts.
RESULTS: In the present study, the cellular behaviors of cardiac fibroblasts induced by Ang II were significantly activated including proliferation, transformation into myofibroblasts and collagen synthesis. Additionally, the ability of cytokine secretion was enhanced obviously. It was demonstrated that treatment of cardiac fibroblasts with berberine resulted in deceased proliferation, and attenuated fibroblast α-smooth muscle actin expression and collagen synthesis. And the protein secretion of TGFβ1 was inhibited; however, the protein secretion of IL-10 was increased in cardiac fibroblasts with berberine treatment. Mechanistically, the phosphorylation level of AMPK was increased; and the phosphorylation levels of mTOR and p70S6K were decreased in berberine treatment group.
CONCLUSION: These results illustrated that the protective effects of berberine on cellular behaviors of cardiac fibroblasts were at least in part due to activate AMPK signaling pathway and downregulate mTOR/p70S6K signaling pathway. Berberine might become a new strategy for treating cardiac fibrosis in the future.

Entities:  

Keywords:  Berberine; cardiac fibroblasts; collagen synthesis; cytokine secretion; proliferation

Mesh:

Substances:

Year:  2015        PMID: 26722438      PMCID: PMC4680383     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  Berberine alleviates ischemic arrhythmias via recovering depressed I(to) and I(Ca) currents in diabetic rats.

Authors:  Li-Hong Wang; Xue-Lian Li; Qiang Li; Ying Fu; Hai-Jing Yu; Yu-Qian Sun; Li Zhang; Hong-Li Shan
Journal:  Phytomedicine       Date:  2011-12-19       Impact factor: 5.340

Review 2.  The dynamic role of cardiac fibroblasts in development and disease.

Authors:  Jacquelyn D Lajiness; Simon J Conway
Journal:  J Cardiovasc Transl Res       Date:  2012-08-10       Impact factor: 4.132

Review 3.  Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends?

Authors:  Melissa L Martin; Burns C Blaxall
Journal:  J Cardiovasc Transl Res       Date:  2012-09-27       Impact factor: 4.132

Review 4.  Importance of myocyte-nonmyocyte interactions in cardiac development and disease.

Authors:  Ying Tian; Edward E Morrisey
Journal:  Circ Res       Date:  2012-03-30       Impact factor: 17.367

5.  Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.

Authors:  Woo Sik Kim; Yun Sok Lee; Seung Hun Cha; Hyun Woo Jeong; Sung Sik Choe; Mi-Ran Lee; Goo Taeg Oh; Hye-Sun Park; Ki-Up Lee; M Daniel Lane; Jae Bum Kim
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-27       Impact factor: 4.310

Review 6.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

Review 7.  Myofibroblasts: Biochemical and proteomic approaches to fibrosis.

Authors:  Eiko Honda; Ah-Mee Park; Koji Yoshida; Masaki Tabuchi; Hiroshi Munakata
Journal:  Tohoku J Exp Med       Date:  2013-06       Impact factor: 1.848

8.  Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: a novel therapeutic approach for cardiac fibrosis.

Authors:  David Lu; Nakon Aroonsakool; Utako Yokoyama; Hemal H Patel; Paul A Insel
Journal:  Mol Pharmacol       Date:  2013-10-01       Impact factor: 4.436

9.  Hepatocyte growth factor regulates the TGF-β1-induced proliferation, differentiation and secretory function of cardiac fibroblasts.

Authors:  Xin Yi; Xiaoyan Li; Yanli Zhou; Shan Ren; Weiguo Wan; Gaoke Feng; Xuejun Jiang
Journal:  Int J Mol Med       Date:  2014-05-16       Impact factor: 4.101

10.  Reversible and irreversible differentiation of cardiac fibroblasts.

Authors:  Ronald B Driesen; Chandan K Nagaraju; Joëlle Abi-Char; Tamara Coenen; Paul J Lijnen; Robert H Fagard; Karin R Sipido; Victor V Petrov
Journal:  Cardiovasc Res       Date:  2013-12-23       Impact factor: 10.787

View more
  16 in total

Review 1.  New Insights Into the Role of mTOR Signaling in the Cardiovascular System.

Authors:  Sebastiano Sciarretta; Maurizio Forte; Giacomo Frati; Junichi Sadoshima
Journal:  Circ Res       Date:  2018-02-02       Impact factor: 17.367

Review 2.  The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair.

Authors:  Parinaz Zivarpour; Željko Reiner; Jamal Hallajzadeh; Liaosadat Mirsafaei; Zatollah Asemi
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

3.  Human cardiac fibroblasts adaptive responses to controlled combined mechanical strain and oxygen changes in vitro.

Authors:  Giovanni Stefano Ugolini; Andrea Pavesi; Marco Rasponi; Gianfranco Beniamino Fiore; Roger Kamm; Monica Soncini
Journal:  Elife       Date:  2017-03-18       Impact factor: 8.140

4.  MiR-429 Regulated by Endothelial Monocyte Activating Polypeptide-II (EMAP-II) Influences Blood-Tumor Barrier Permeability by Inhibiting the Expressions of ZO-1, Occludin and Claudin-5.

Authors:  Liangyu Chen; Yixue Xue; Jian Zheng; Xiaobai Liu; Jing Liu; Jiajia Chen; Zhen Li; Zhuo Xi; Hao Teng; Ping Wang; Libo Liu; Yunhui Liu
Journal:  Front Mol Neurosci       Date:  2018-02-07       Impact factor: 5.639

Review 5.  Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.

Authors:  Xiaojun Feng; Antoni Sureda; Samineh Jafari; Zahra Memariani; Devesh Tewari; Giuseppe Annunziata; Luigi Barrea; Sherif T S Hassan; Karel Šmejkal; Milan Malaník; Alice Sychrová; Davide Barreca; Lovro Ziberna; Mohamad Fawzi Mahomoodally; Gokhan Zengin; Suowen Xu; Seyed Mohammad Nabavi; Ai-Zong Shen
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

Review 6.  The role of post-translational modifications in cardiac hypertrophy.

Authors:  Kaowen Yan; Kun Wang; Peifeng Li
Journal:  J Cell Mol Med       Date:  2019-04-04       Impact factor: 5.310

7.  MicroRNA‑212 facilitates the motility and invasiveness of esophageal squamous carcinoma cells.

Authors:  Zhi Chen; Yuzhen Liu; Bo Qi; Chengwei Gu; Xiufeng Wei; Ling Guo; Wenjian Yao; Baosheng Zhao
Journal:  Mol Med Rep       Date:  2019-09-03       Impact factor: 2.952

8.  Yes-Associated Protein (Yap) Is Up-Regulated in Heart Failure and Promotes Cardiac Fibroblast Proliferation.

Authors:  Maryam Sharifi-Sanjani; Mariah Berman; Dmitry Goncharov; Mohammad Alhamaydeh; Theodore Guy Avolio; Jeffrey Baust; Baojun Chang; Ahasanul Kobir; Mark Ross; Claudette St Croix; Seyed Mehdi Nouraie; Charles F McTiernan; Christine S Moravec; Elena Goncharova; Imad Al Ghouleh
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

9.  Activation of AMPK inhibits TGF-β1-induced airway smooth muscle cells proliferation and its potential mechanisms.

Authors:  Yilin Pan; Lu Liu; Shaojun Li; Ke Wang; Rui Ke; Wenhua Shi; Jian Wang; Xin Yan; Qianqian Zhang; Qingting Wang; Limin Chai; Xinming Xie; Manxiang Li
Journal:  Sci Rep       Date:  2018-02-26       Impact factor: 4.379

Review 10.  Cellular stress response mechanisms of Rhizoma coptidis: a systematic review.

Authors:  Jin Wang; Qian Ran; Hai-Rong Zeng; Lin Wang; Chang-Jiang Hu; Qin-Wan Huang
Journal:  Chin Med       Date:  2018-06-07       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.